Want the short version?
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Russell Skibsted is Chief Financial Officer at Processa Pharmaceuticals. OQRO lists 8 transactions filed with the SEC under this name, the latest on Jul 29, 2026, each linked to the official Form 4.
Chief Financial Officer
Disclosures on record
8
Companies involved
1
7 buys, median −26.0 pts vs S&P 500, beat it 0 of 7 times.
Average −26.2 pts vs S&P 500. Each buy is one disclosure of open-market purchases in one company on one filing date, filed Apr 2, 2026 to Jul 2, 2026, measured from the first close after the filing. Past results, not a forecast.
7 purchases disclosed; 0% of the 7 measured at 90 days finished ahead of the index. $1,000 placed after each of the 7 purchases disclosed since 2025-11-16 would be worth $5.2K today ($7K put in); the same in the S&P 500 (SPY): $7.3K.
Not ranked: fewer than 10 purchases measured at 90 days. The middle of the 82 ranked insiders is −5.5 pts (median, against the S&P 500).
Processa PharmaceuticalsPCSA
8 disclosures · Apr 2026 – Jul 2026 · 7 bought
Jul 26, 202612Kdisclosed Jul 29
DetailsOfficial recordJun 30, 2026Bought~$6.3Kdisclosed Jul 2
DetailsEqual weight counts every purchase once; by size counts it for its disclosed dollars. Both are measured from the first close after it was reported. Past results describe the past, not a forecast. How this is measured · Leaderboard
Jun 15, 2026Bought~$5.9Kdisclosed Jun 17
DetailsOfficial recordMay 29, 2026Bought~$5.9Kdisclosed Jun 2
DetailsOfficial recordMay 15, 2026Bought~$5.9Kdisclosed May 20
DetailsOfficial recordApr 30, 2026Bought~$5.9Kdisclosed May 2
DetailsOfficial recordApr 15, 2026Bought~$5.9Kdisclosed Apr 18
DetailsOfficial recordMar 31, 2026Bought~$5.9Kdisclosed Apr 2
DetailsOfficial recordAs of the latest filing on , Russell Skibsted reported holding 16,689 shares of Processa Pharmaceuticals (PCSA), worth about $29K at the last close of $2 (Nov 16, 2026). In the last 12 months, Russell Skibsted bought $42K in 7 open-market purchases.
| Company | Shares reported | How held | Last close | Value at last close | Reported |
|---|---|---|---|---|---|
| Processa Pharmaceuticals PCSA | 16,689 | 17K direct | $2 | $29K | Jun 30, 2026 |
Is this Russell Skibsted’s net worth? No. A Form 4 reports the shares an insider owns in one company after each transaction, directly or through trusts and entities. It says nothing about cash, other investments, property or debt, options not yet exercised are not counted here, and a holding reported some time ago may have changed without a new filing. The value is shares times the last stored close, not a price anyone received. Sources: the filings listed below, each linked to EDGAR. Compare with the biggest insider stakes.
Russell Skibsted bought shares on the open market in 2017 and 2026 across 2 companies.
Russell Skibsted reported 8 open-market purchases and 0 sales since 2017; purchases in 2 different years, most recently 2026.
| Year | Bought | Sold |
|---|---|---|
| 2026 | $42K7×7 trades | — |
| 2017 | $5.3K1×1 trade | — |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
On the latest SEC Form 4, dated Jun 30, 2026, Russell Skibsted reported holding 16,689 shares of Processa Pharmaceuticals (PCSA). At the last close of $2 on Nov 16, 2026, that is about $29K. This is the stake disclosed in filings, not a net worth.
In SEC filings of the last 12 months, Russell Skibsted reported 7 open-market purchases worth $42K, and no open-market sale. Shares withheld for taxes, gifts and option exercises are not counted in these totals.
Russell Skibsted bought shares on the open market in 2017 and 2026 across 2 companies.
In SEC filings since 2017: the latest open-market purchase is from 2026; no open-market sale is on record.
2 companies: Processa Pharmaceuticals (PCSA, 2026), Lineage Cell Therapeutics (LCTX, 2017).
Russell Skibsted reported 7 open-market purchases and 0 sales here, 2026.
Russell Skibsted reported 1 open-market purchase and 0 sales here, 2017.
Closing prices and the companies' last annual figures; a − or + is a fact of the close, not a forecast.